Deals
Shire Quarterly Profit Tops Estimates as Drug Sales Soar
- Baxalta acquisition scheduled to be completed in early June
- Shares climb by most in more than three weeks in London
This article is for subscribers only.
Shire Plc reported first-quarter earnings that beat analysts’ estimates as sales climbed for its key ADHD drug and medicines to treat rare diseases obtained in last year’s acquisition of NPS Pharmaceuticals Inc.
Earnings per American depositary shares rose to $3.19, the Dublin-based company said in a statement on Friday. That compared with the $3.05 average of 15 analysts’ estimates compiled by Bloomberg. Sales grew 15 percent to $1.71 billion.